Polysaccharide Conjugation and the Infant Thymus

Oswald Avery's Hapten Principle and How John Robbins and Rachel Schneerson Defeated Haemophilus Meningitis

Prior to the late 1980s, the leading cause of acquired mental retardation, post-infectious sensorineural deafness, and bacterial meningitis in young children across the developed world was Haemophilus influenzae type b (Hib). Colonizing the nasopharynx and invading the bloodstream and meninges of roughly 20,000 American children under age five every year, Hib killed 5 percent of its meningitis victims despite intravenous antibiotics and left 20 to 30 percent of survivors with permanent neurological sequelae. Like Streptococcus pneumoniae and Neisseria meningitidis, Hib evades phagocytic clearance in the bloodstream by wrapping itself in a thick, hydrophilic extracellular capsule composed of a repeating sugar polymer. In Hib's case, that capsule is polyribosylribitol phosphate (PRP), a linear chain of ribose, ribitol, and phosphate units that masks bacterial surface proteins and prevents complement component C3b opsonization.

When purified PRP capsular polysaccharide was tested as a vaccine among 100,000 children in Finland in 1974 by Helena Mäkelä, Heikki Peltola, and John Robbins, the results exposed a stark developmental fault line in human immunology. Children vaccinated after eighteen to twenty-four months of age generated protective anti-PRP antibodies and experienced a 90 percent drop in invasive Hib disease. In infants under eighteen months—the exact demographic window where transplacental maternal $\text{IgG}$ wanes and more than 75 percent of fatal Hib meningitis cases occur—the pure polysaccharide vaccine produced virtually zero antibody response, zero booster recall upon re-injection, and zero clinical protection.

The failure of pure carbohydrate vaccines in infants stems from the strict peptide-only specificity of Major Histocompatibility Complex Class II (MHC-II) molecules and helper T cells. Because long polysaccharide chains consist of dozens of identical repeating monosaccharide units, they bind and physically cross-link multiple B-cell receptors (BCRs) simultaneously on the surface of a polysaccharide-specific B cell, acting as a T-cell-independent type 2 (TI-2) antigen. In adults, a specialized subset of marginal-zone B cells residing in the splenic white pulp responds to TI-2 receptor cross-linking by secreting short-lived, low-affinity pentameric $\text{IgM}$ and limited $\text{IgG2}$ without T-cell assistance. In human infants under twenty-four months, however, the splenic marginal zone is anatomically immature. Worse, when any B cell internalizes a pure polysaccharide by receptor-mediated endocytosis, endosomal proteases cannot cleave the carbohydrate into peptides that fit the binding groove of MHC-II molecules. Without MHC-II peptide presentation on its surface, the B cell cannot engage $\text{CD4}^+$ follicular helper T cells (Tfh). It never receives $\text{CD40L}$ costimulation or interleukin-21 signaling, cannot form a germinal center, fails to undergo activation-induced cytidine deaminase (AID) somatic hypermutation or class-switch recombination to high-affinity $\text{IgG1}$, and generates no memory B cells.

To bypass this infant bottleneck, John Robbins and Rachel Schneerson at the National Institute of Child Health and Human Development in Bethesda—alongside Porter Anderson and David Smith at the University of Rochester—returned to a foundational 1929 Rockefeller Institute experiment by Oswald Avery and Walther Goebel. Avery and Goebel had demonstrated that chemically coupling pneumococcal type III capsular polysaccharide to horse serum globulin rendered the non-immunogenic sugar strongly immunogenic in rabbits. In 1980, Schneerson and Robbins used cyanogen bromide activation and adipic acid dihydrazide spacers to form stable covalent bonds linking purified Hib PRP polysaccharide to immunogenic protein carriers such as tetanus toxoid, diphtheria toxoid, the non-toxic diphtheria mutant CRM197, or meningococcal outer-membrane protein.

This glycoconjugate architecture exploits the mechanism of linked recognition between B and T lymphocytes. In an infant at two months of age, a naive B cell whose surface receptor is strictly specific for the PRP sugar polymer binds the carbohydrate portion of the conjugate molecule and internalizes the entire covalently linked complex into its endosome. Inside the endolysosome, cathepsin proteases digest the attached tetanus or diphtheria carrier protein into twelve-to-fifteen-amino-acid peptides, which load onto MHC-II molecules and traffic to the B-cell surface. Follicular helper T cells previously primed against that same carrier peptide recognize the MHC-II complex, engage the B cell's $\text{CD40}$ receptor, and drive the PRP-specific B cell into a full germinal-center reaction. Although the helper T cell recognizes only the protein carrier, the B cell it stimulates secretes high-affinity, class-switched $\text{IgG1}$ antibodies directed exclusively against the bacterial PRP sugar capsule. Following the December 1990 approval of infant Hib conjugate vaccines—and the extension of polysaccharide-protein conjugation to pneumococcal and meningococcal vaccines—invasive Hib meningitis in young children fell by more than 99 percent, while high mucosal $\text{IgG}$ transudation eliminated nasopharyngeal carriage across the herd.